About Metacrine
Metacrine is a company based in San Diego (United States) founded in 2015. Metacrine has raised $124.77 million across 4 funding rounds from investors including ARE, Franklin Templeton and Arch Venture Partners. The company has 32 employees. Metacrine offers products and services including FXR Program. Metacrine operates in a competitive market with competitors including NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, Corcept and ViaCyte, among others.
- Headquarter San Diego, United States
- Employees 32
- Stage Public
- SectorsHealthcare
- Website metacrine.com
- Social LinkedIn
- Net Profit-$62.21 M (USD)-67as on Dec 31, 2021
- EBITDA-$61.08 M (USD)-66as on Dec 31, 2021
- Total Equity Funding$124.77M (USD)
in 4 rounds
- Latest Funding Round$50M (USD), Debt – Conventional
Sep 2019
- InvestorsARE
& 14 more
- Employee Count32
Products & Services of Metacrine
Metacrine offers a comprehensive portfolio of products and services, including FXR Program.
Develops therapies targeting FXR for gastrointestinal and liver diseases.
Funding Insights of Metacrine
Metacrine has successfully raised a total of $124.77M across 4 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $50 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $124.77M
- Total Rounds 4
- Last Round Debt – Conventional — $50M
- First Round $37.77M
(Nov 2016)
- Investors Count 15
All 4 funding rounds of Metacrine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2019 | $50M | Debt – Conventional | – | – | |
| Jun 2018 | $65M | Series C | – | Venrock | |
| Dec 2017 | $22M | Series B | – | New Enterprise Associates | |
| Nov 2016 | $37.77M | Series A | – | Arch Venture Partners, EcoR1 | – |
15 investors in total: 15 institutional.
Investors in Metacrine
Metacrine has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Franklin Templeton and Arch Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Flexible, long-term financing solutions are provided to healthcare companies. | – | k2hv.com | Boston, United States | |
Venture capital firm focused on tech sectors | – | venrock.com | Palo Alto, United States | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | – | deerfield.com | New York, United States | |
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States | |
Venture capital and private equity firm | – | vivocapital.com | Palo Alto, United States | |
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
US focused venture capital firm | – | polarispartners.com | Boston, United States | |
Venture capital investments are offered to startups by NEA. | – | nea.com | Menlo Park, United States | |
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
Healthcare startups are funded by this corporate-backed venture capital entity. | – | lifesciventure.com | New York, United States |
Investor details for Metacrine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Metacrine
8 people are tracked at Metacrine (3 in leadership, 3 in board & advisors, 2 in team); the tracked headcount is 32.
| Name | Role | Group |
|---|---|---|
Theresa Lowry | VP, Human Resources | Leadership |
Rob Mansfield | Executive Director | Leadership |
Jonathan Lee | Director Clinical Operations | Leadership |
John Mchutchison | Director | Board & advisors |
Ronald Evans | Director | Board & advisors |
Richard Heyman | Chairman | Board & advisors |
E GARCIA | Accounts Payable Clerk | Team |
Alvaro Ortiz | Scientist | Team |
Complete people profiles for Metacrine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Metacrine
4 dated milestones of Metacrine across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Metacrine is founded.
- Funding First funding round of $37.8M.
- Funding Latest funding round, Debt – Conventional, of $50.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Metacrine
Metacrine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, Corcept and ViaCyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| corcept.com | 1998 | Menlo Park, United States | – | 352 | Developer of cortisol modulators for the treatment of various diseases | |
| viacyte.com | 1999 | San Diego, United States | $389.03M | 126 | Cell therapy for diabetes is developed from stem cells. | |
| 89bio.com | 2018 | San Francisco, United States | $60M | 70 | Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders | |
| genfit.com | 1999 | Loos, France | – | – | Therapeutics for cardiometabolic and neurodegenerative diseases. | |
| alnara.com | 2008 | Cambridge, United States | $55M | – | Protein therapeutics for metabolic diseases are developed orally. | |
| enobia.com | 1997 | Quebec, Canada | $138.52M | – | Therapies for genetic metabolic bone disorders are developed. |
Detailed competitors of Metacrine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Metacrine
Complete news archive for Metacrine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Metacrine
10 companies that operate in the same segment as Metacrine (Metabolic Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Developer of cortisol modulators for the treatment of various diseases | 1998 | Menlo Park, California, United States | – | USD 761.41 M | 500 | |
Developer of therapies for the treatment of endocrine-related diseases and cancers | 2008 | San Diego, California, United States | USD 103.5 M | USD 1.04 M | 437 | |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | 2009 | Cambridge, Massachusetts, United States | USD 685 M | – | 81 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Solutions for biomarker discovery and diagnostic testing are provided. | 2000 | Morrisville, United States | USD 165.87 M | – | – | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Metacrine
Metacrine was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Metacrine is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Metacrine is a funded company, having raised a total of $124.77M across 4 funding rounds to date. The company's 1st funding round was a Series A of $37.77M, raised on Nov 2016.
Metacrine has 32 employees.
Metacrine is a developer of protein sensitizers for insulin in type 2 diabetes and modulators for metabolic diseases. It has developed a product candidate, MET409 has been investigated in a Phase 1b proof-of-concept clinical trial in NASH patients, in which it demonstrated notable improvements in NASH biomarkers after 12 weeks of treatment.
Metacrine's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
Metacrine offers FXR Program.
Metacrine has 15 investors. Key investors include ARE, Franklin Templeton, Arch Venture Partners, ArrowMark Partners, and K2 HealthVentures.